PEAK6’s Ascendis Pharma A/S ASND Stock Holding History

PEAK6’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.29M	Hold	10,000	–	–	0.01%	1310
2025 Q4	$2.13M	Buy	+10,000	New	+$2.07M	﹤0.01%	1404

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PEAK6's ASND Position: Q1 2026 in Review

PEAK6 sold out of Ascendis Pharma A/S (ASND) in Q1 2026, closing a stake of 2 shares — an estimated $448 sold.

PEAK6 first reported a position in ASND in Q4 2025 and held it in 1 quarter. The position peaked at $500 in Q4 2025. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

PEAK6 reported no remaining Ascendis Pharma A/S position as of Q1 2026 after selling out during the quarter.
PEAK6 sold 2 Ascendis Pharma A/S shares in Q1 2026, an estimated $448.
PEAK6 first reported a position in Ascendis Pharma A/S in Q4 2025 and held it in 1 quarter.
PEAK6's Ascendis Pharma A/S position peaked at $500 in Q4 2025.
273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on PEAK6's 13F filing for Q1 2026, filed 14 May 2026.